

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method for determining whether an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs and cisplatin derivatives can be used to reduce the growth of a an ovarian tumor, comprising the steps of:
 - a) obtaining a sample of ovarian tumor cells;
 - b) determining whether the ovarian tumor cells express one or more sensitivity markers identified in Tables 1-6; and
 - c) identifying that ~~an~~ the agent can be used to reduce the growth of the ovarian tumor cells when the one or more sensitivity markers are expressed.
2. **(Withdrawn – Currently Amended)** The method of claim 1, wherein the agent is TAXOL, a TAXOL mimic, a TAXOL analog, or a TAXOL derivative ~~a taxane compound~~.
3. **(Withdrawn – Currently Amended)** The method of claim 1, wherein the agent is cisplatin, a cisplatin mimic, a cisplatin analog, or a cisplatin derivative ~~a platinum compound~~.
4. **(Currently Amended)** The method of claim 1, wherein the agent is a combination of two or more agents consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs and cisplatin derivatives ~~a taxane compound and a platinum compound~~.
5. **(Currently Amended)** The method of claim ~~1~~ 70, wherein ~~the level of~~ expression is determined by detecting the amount of SEQ ID NO:16 mRNA ~~that is encoded by the one or more markers present in the sample~~.
6. **(Currently Amended)** The method of claim ~~1~~ 70, wherein ~~the level of~~ expression is determined by detecting the amount of protein that is encoded by SEQ ID NO:16 ~~said one or more markers present in the sample~~.
7. **(Currently Amended)** The method of claim 1, wherein said ovarian tumor cells are obtained from a an ovarian tumor cell line or a an ovarian tumor obtained from a subject.

8. **(Currently Amended)** A method for determining whether an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs and cisplatin derivatives cannot be used to reduce the growth of a an ovarian tumor, comprising the steps of:

- a) obtaining a sample of ovarian tumor cells;
- b) determining whether the ovarian tumor cells express one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1-6; and
- c) identifying that ~~an~~ the agent cannot be used to reduce the growth of the ovarian tumor when one or more of the sensitivity markers in Tables 1-6 is not expressed or is underexpressed by the ovarian tumor cells.

9. **(Withdrawn – Currently Amended)** The method of claim 8, wherein the agent is TAXOL, a TAXOL mimic, a TAXOL analog, or a TAXOL derivative ~~a taxane compound~~.

10. **(Withdrawn – Currently Amended)** The method of claim 8, wherein the agent cisplatin, a cisplatin mimic, a cisplatin analog, or a cisplatin derivative ~~a platinum compound~~.

11. **(Currently Amended)** The method of claim 8, wherein the agent is a combination of two or more agents consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs and cisplatin derivatives ~~a taxane compound and a platinum compound~~.

12. **(Currently Amended)** The method of claim 8 71, wherein ~~the level of~~ expression is determined by detecting the amount of SEQ ID NO:16 mRNA ~~that is encoded by the one or more sensitivity markers present in the sample~~.

13. **(Currently Amended)** The method of claim 8 71, wherein ~~the level of~~ expression is determined by detecting the amount of protein that is encoded by SEQ ID NO:16 ~~said one or more markers present in the sample~~.

14. **(Currently Amended)** The method of claim 8, wherein said ovarian tumor cells are obtained from a an ovarian tumor cell line or a an ovarian tumor obtained from a subject.

15-69. **(Cancelled)**

70. **(New)** The method of claim 1, wherein the sensitivity marker is the marker of SEQ ID NO:16.

71. **(New)** The method of claim 8, wherein the sensitivity marker is the marker of SEQ ID NO:16.